Abnormal levels of metalloproteinases, including MMP-9, in plasma have been associated with AD progression (Iturria-Medina et al., 2016) and increased permeability of the blood-brain barrier, a driver of cognitive impairment (Montagne et al., 2020). Here, MMP9 is linked to Alzheimer disease.